Spiolto Respimat

Spiolto Respimat

Nhà sản xuất:

Boehringer Ingelheim
Thông tin kê toa chi tiết tiếng Anh
Contents
Tiotropium bromide, olodaterol.
Description
The SPIOLTO RESPIMAT is a soft mist inhaler delivering tiotropium + olodaterol inhalation solution.
The delivered dose is 2.5 microgram tiotropium and 2.5 microgram olodaterol per puff (2 puffs comprise one medicinal dose) and is equivalent to 3.124 microgram tiotropium bromide monohydrate and 2.736 microgram olodaterol hydrochloride.
(INN = tiotropium bromide).
(INN = olodaterol).
The delivered dose is the dose which is available for the patient after passing the mouthpiece.
Excipients/Inactive Ingredients: Benzalkonium chloride, Disodium edetate, purified water, hydrochloric acid 1M, nitrogen.
Action
Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with anticholinergics. ATC code: RO3ALxx.
Pharmacology: Pharmacodynamics: Mode of action: Tiotropium, a long acting muscarinic antagonist and olodaterol a long acting beta2-adrenergic are administered together in the SPIOLTO RESPIMAT soft mist inhaler. These two active ingredients provide additive bronchodilation due to their different mode of action and different locations of the target receptors in the lungs.
Tiotropium: Tiotropium bromide is a long-acting, muscarinic receptor antagonist (LAMA), in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3-receptors at the smooth muscle results in relaxation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In pre-clinical in vitro as well as in vivo studies bronchoprotective effects were dose-dependent and lasted longer than 24 hours. The long duration of the effect is likely to be due to its very slow dissociation from M3-receptors, exhibiting a significantly longer dissociation half-life than that seen with ipratropium. As an N-quaternary anticholinergic tiotropium is topically (broncho-) selective when administered by inhalation, demonstrating an acceptable therapeutic range before giving rise to systemic anti-cholinergic effects. Dissociation from M2-receptors is faster than from M3, which in functional in vitro studies, elicited (kinetically controlled) receptor subtype selectivity of M3 over M2.
The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD.
The bronchodilation following inhalation of tiotropium is primarily a local effect (on the airways) not a systemic one.
Olodaterol: Olodaterol has a high affinity and high selectivity to the human beta2-adrenoceptor. In vitro studies have shown that olodaterol has 241-fold greater agonist activity at beta2-adrenoceptors compared to beta1-adrenoceptors and 2299-fold greater agonist activity compared to beta3-adrenoceptors. The compound exerts its pharmacological effects by binding and activation of beta2-adrenoceptors after topical administration by inhalation.
Activation of these receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3',5' adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells. Olodaterol has the pre-clinical profile of a long-acting selective beta2-adrenoceptor agonist (LABA) with a fast onset of action and duration of action of at least 24 hours.
Beta-adrenoceptors are divided into three subtypes, beta1-adrenoceptors predominantly expressed on cardiac muscle, beta2-adrenoceptors predominantly expressed on airway smooth muscle and beta3-adrenoceptors predominantly expressed on adipose tissue. Beta2-agonists cause bronchodilation. Although the beta2-adrenoceptor is the predominant adrenergic receptor in the airway smooth muscle it is also present on the surface of a variety of other cells, including lung epithelial and endothelial cells and in the heart. The precise function of beta2-receptors in the heart is not known, but their presence raises the possibility that even highly selective beta2-adrenergic agonists may have cardiac effects.
Clinical studies: Effects on cardiac electrophysiology: Tiotropium: The effect of tiotropium (inhalation powder 18 and 54 microgram once daily) on the QT/QTc interval of the ECG was investigated in 56 healthy male and female volunteers in a double-blind, randomised, placebo- and active (moxifloxacin) controlled study. The mean changes from baseline in QT interval over 5 minutes to 2 hours after dosing on day 12 was -1.4 ms for placebo, +0.6 ms for 18 microgram tiotropium and -2.1 ms for 54 microgram tiotropium; the upper limit of the one-sided 95% confidence intervals of the placebo-adjusted difference from baseline was less than 10 ms for both tiotropium doses (+4.9 ms for 18 microgram tiotropium, +2.2 ms for 54 microgram tiotropium).
Olodaterol: The effect of olodaterol on the QT/QTc interval of the ECG was investigated in 24 healthy male and female volunteers in a double-blind, randomised, placebo- and active (moxifloxacin) controlled study. Olodaterol at single doses of 10, 20, 30 and 50 microgram, demonstrated that compared with placebo, the mean changes from baseline in QT interval over 20 minutes to 2 hours after dosing increased dose-dependently from 1.6 (10 microgram olodaterol) to 6.5 ms (50 microgram olodaterol), with the upper limit of the two-sided 90% confidence intervals being less than 10 ms at all dose levels.
The effect of 5 microgram and 10 microgram olodaterol on heart rate and rhythm was assessed using continuous 24-hour ECG recording (Holter monitoring) in a subset of 772 patients in the 48-week, placebo-controlled Phase 3 Trials. There were no dose- or time-related trends or patterns observed for the magnitudes of mean changes in heart rate or premature beats. Shifts from baseline to the end of treatment in premature beats did not indicate meaningful differences between olodaterol 5 microgram, 10 microgram and placebo.
Spiolto Respimat: In two 52-week randomized, double-blind trials using SPIOLTO RESPIMAT that enrolled 5162 patients with COPD, ECG assessments were performed post-dose on days 1, 85, 169, and 365. In a pooled analysis the number of subjects with changes from baseline-corrected QT interval of >30 msec using both the Bazett (QTcB) and Fredericia (QTcF), corrections of QT for heart rate ranged from 4.9-6.4% (QTcB) and 3.3-4.7% (QTcF) for the SPIOLTO RESPIMAT group compared to 5.0-6.0% (QTcB) and 3.4-4.4% (QTcF) for olodaterol 5 microgram and 5.3-6.5% (QTcB) and 3.0-4.7% (QTcF) for tiotropium 5 microgram across the assessments conducted.
Clinical efficacy and safety: The Phase III clinical development program for SPIOLTO RESPIMAT included three randomised, double-blind trials: (i) two replicate, 52 week parallel group trials comparing SPIOLTO RESPIMAT with tiotropium 5 microgram and olodaterol 5 microgram (1029 received SPIOLTO RESPIMAT) [Trials 1 and 2]; (ii) one 6 week cross-over trial comparing SPIOLTO RESPIMAT with tiotropium 5 microgram and olodaterol 5 microgram and placebo (139 received SPIOLTO RESPIMAT) [Trial 3].
In these trials, the comparator products, tiotropium 5 microgram, olodaterol 5 microgram and placebo, were administered via the RESPIMAT inhaler.
All studies included lung function measurements (forced expiratory volume in one second, FEV1). In the 52 week studies, lung function was measured up to 3 hrs post-dose (12 hrs post-dose in a sub-set of patients) and at 23-24 hrs post-dose; the primary lung function efficacy endpoints were change from pre-treatment baseline (response) in FEV1 AUC0-3h and trough FEV1 after 24 weeks. In the 6 week study, lung function was measured up to 12 hrs post-dose and at 22-24 hrs post-dose; the primary efficacy endpoint was FEV1 AUC0-24h response after 6 weeks. The 52 week trials also included the St. George's Respiratory Questionnaire (SGRQ) as a primary endpoint as a measure of health-related quality of life and the Mahler Transition Dyspnoea Index (TDI) as a key secondary endpoint as a measure of dyspnoea.
Patients enrolled into the Phase III program were 40 years of age or older with a clinical diagnosis of COPD, had a smoking history of more than 10 pack years and had moderate to very severe pulmonary impairment (post-bronchodilator FEV1 less than 80% predicted normal (GOLD Stage 2-4); post-bronchodilator FEV1 to FVC ratio of less than 70%).
Patient characteristics: The majority of the 5162 patients recruited in the global, 52 week trials [Trials 1 and 2] were male (73%), white (71%) or Asian (25%), with a mean age of 64.0 years. Mean post-bronchodilator FEV1 was 1.37 L (GOLD 2 [50%], GOLD 3 [39%], and GOLD 4 [11%]). Mean β2-agonist responsiveness was 16.6% of baseline (0.171 L). Pulmonary medications allowed as concomitant therapy included inhaled steroids [47%] and xanthines [10%].
The 6 week trial [Trial 3] was conducted in Europe and North America. The majority of the 219 recruited patients were male (59%) and white (99%), with a mean age of 61.1 years. Mean post-bronchodilator FEV1 was 1.55 L (GOLD 2 [64%], GOLD 3 [34%], GOLD 4 [2%]). Mean β2-agonist responsiveness was 15.9% of baseline (0.193 L). Pulmonary medications allowed as concomitant therapy included inhaled steroids [41%] and xanthines [4%].
Lung function: In the 52 week trials, SPIOLTO RESPIMAT, administered once daily in the morning, provided clear improvement in lung function within 5 minutes after the first dose compared to tiotropium 5 microgram (mean increase in FEV1 of 0.137 L for SPIOLTO RESPIMAT vs. 0.058 L for tiotropium 5 microgram [p<0.0001] and 0.125 L for olodaterol 5 microgram [p=0.16]). In both studies, significant improvements were observed in FEV1 AUC0-3h response and trough FEV1 response after 24 weeks (lung function primary endpoints) for SPIOLTO RESPIMAT compared to tiotropium 5 microgram and olodaterol 5 microgram (Table 1). (See Table 1.)


Click on icon to see table/diagram/image


The increased bronchodilator effects of SPIOLTO RESPIMAT compared to tiotropium 5 microgram and olodaterol 5 microgram were maintained throughout the 52 week treatment period. SPIOLTO RESPIMAT also improved morning and evening PEFR (peak expiratory flow rate) compared to tiotropium 5 microgram and olodaterol 5 microgram as measured by patient's daily recordings.
In the sub-set of patients who completed extended lung function measurements up to 12 hrs post-dose, SPIOLTO RESPIMAT showed a significantly greater FEV1 response compared to tiotropium 5 microgram and olodaterol 5 microgram over the full 24 hour dosing interval (Figure 1, Table 2). (See Figure 1 and Table 2.)


Click on icon to see table/diagram/image




Click on icon to see table/diagram/image


In the 6 week trial, SPIOLTO RESPIMAT showed a significantly greater FEV1 response compared to tiotropium 5 microgram, olodaterol 5 microgram and placebo over the full 24 hour dosing interval (Figure 2, Table 3). (See Figure 2 and Table 3.)


Click on icon to see table/diagram/image




Click on icon to see table/diagram/image


Health-related Quality of Life: After 24 weeks, SPIOLTO RESPIMAT significantly improved mean SGRQ total score compared to tiotropium 5 microgram and olodaterol 5 microgram (Table 4); improvements were seen in all SGRQ domains. More patients treated with SPIOLTO RESPIMAT had a clinically meaningful improvement in SGRQ total score (MCID, defined as a decrease of at least 4 units from baseline) compared to tiotropium 5 microgram (57.5% vs. 48.7%, p=0.0001) and olodaterol 5 microgram (57.5% vs. 44.8%, p<0.0001). (See Table 4.)


Click on icon to see table/diagram/image


In two additional 12-week, placebo-controlled clinical trials, SGRQ total score at 12 weeks was also included as primary endpoint as a measure of health-related quality of life.
In the 12-week trials, SPIOLTO RESPIMAT demonstrated an improvement compared with placebo at week 12 in mean SGRQ total score (primary endpoint) of -4.9 (95%CI: -6.9, -2.9; p<0.0001) and -4.6 (95%CI: -6.5, -2.6; p<0.0001). In a pooled analysis of the 12-week trials, the proportion of patients with a clinically meaningful decrease in SGRQ total score (defined as a decrease of at least 4 units from baseline) at week 12 was greater for SPIOLTO RESPIMAT (52%) compared with tiotropium 5 microgram (41%; odds ratio: 1.56 (95%CI: 1.17, 2.07), p = 0.0022) and placebo (32%; odds ratio: 2.35 (95%CI: 1.75, 3.16), p < 0.0001).
Dyspnoea: After 24 weeks, SPIOLTO RESPIMAT significantly improved mean TDI focal score compared to tiotropium 5 microgram and olodaterol 5 microgram (Table 5). More patients treated with SPIOLTO RESPIMAT had a clinically meaningful improvement in TDI focal score (MCID, defined as a value of at least 1 unit) compared to tiotropium 5 microgram (54.9% vs. 50.6%, p=0.0546) and olodaterol 5 microgram (54.9% vs. 48.2%, p=0.0026). (See Table 5.)


Click on icon to see table/diagram/image


Rescue Medication Use: Patients treated with SPIOLTO RESPIMAT used less daytime and night-time rescue salbutamol compared to patients treated with tiotropium 5 microgram and olodaterol 5 microgram.
Patient Global Rating: Patients treated with SPIOLTO RESPIMAT perceived a greater improvement in their respiratory condition compared to tiotropium 5 microgram and olodaterol 5 microgram, as measured by a Patient's Global Rating (PGR) scale.
Exacerbations: Tiotropium 5 microgram has previously demonstrated a statistically significant reduction in risk of a COPD exacerbation compared to placebo. COPD exacerbations was included as an additional endpoint in the 52 week pivotal trials (Trials 1 and 2). In the combined dataset, the proportion of patients experiencing a moderate/severe COPD exacerbation was 27.7% for SPIOLTO RESPIMAT and 28.8% for tiotropium 5 microgram.
Inspiratory capacity, breathing discomfort and exercise endurance: The effect of SPIOLTO RESPIMAT on inspiratory capacity, breathing discomfort and symptom-limited exercise endurance was investigated in three randomised, double-blind trials in COPD patients: (i) two replicate, 6 week cross-over trials comparing SPIOLTO RESPIMAT with tiotropium 5 microgram, olodaterol 5 microgram and placebo during constant work rate cycling (450 received SPIOLTO RESPIMAT) [Trials 4 and 5]; (ii) one 12 week parallel group trial comparing SPIOLTO RESPIMAT with placebo during constant work rate cycling (139 received SPIOLTO RESPIMAT) and constant speed walking (sub-set of patients) [Trial 6].
SPIOLTO RESPIMAT significantly improved inspiratory capacity compared to tiotropium 5 microgram, olodaterol 5 microgram and placebo after 6 weeks (Trials 4 and 5; Table 6) and compared to placebo after 12 weeks (0.234 L, p<0.0001; Trial 6). (See Table 6.)


Click on icon to see table/diagram/image


In Trials 4 and 5, SPIOLTO RESPIMAT improved endurance time during constant work rate cycling by 20.9% and 13.4% compared to placebo (Table 7). In Trial 6, SPIOLTO RESPIMAT improved endurance time during constant work rate cycling by 12.6% after the first dose (in a sub-set of patients), by 22.9% after 6 weeks and by 13.8% after 12 weeks compared to placebo and increased endurance time during constant speed walking (in a sub-set of patients) by 20.6% after 6 weeks and by 20.9% after 12 weeks compared to placebo (Table 8). (See Tables 7 and 8.)


Click on icon to see table/diagram/image




Click on icon to see table/diagram/image


In Trials 4 and 5, SPIOLTO RESPIMAT decreased the slope of breathing discomfort during constant work rate cycling compared to placebo (p<0.0005; Table 9). (See Table 9.)


Click on icon to see table/diagram/image


Pharmacokinetics: When tiotropium and olodaterol were administered in combination by the inhaled route, the pharmacokinetic parameters for each component were similar to those observed when each active substance was administered separately.
Tiotropium and olodaterol demonstrate linear pharmacokinetics in the therapeutic range. On repeated once-daily inhalation administration, steady state of tiotropium is reached by day 7. Steady state of olodaterol is achieved after 8 days of once-daily inhalation, and accumulation is up to 1.8-fold as compared to a single dose.
Absorption: Tiotropium: Urinary excretion data from young healthy volunteers suggests that approximately 33% of the dose inhaled via the RESPIMAT inhaler reaches the systemic circulation. The absolute bioavailability from an orally administered solution was found to be 2-3%. Maximum tiotropium plasma concentrations are observed 5-7 minutes after the inhalation via RESPIMAT.
Olodaterol: In healthy volunteers the absolute bioavailability of olodaterol following inhalation was estimated to be approximately 30%, whereas the absolute bioavailability was below 1% when given as an oral solution. Maximum olodaterol plasma concentrations generally are reached within 10 to 20 minutes following drug inhalation via RESPIMAT.
Distribution: Tiotropium has a plasma protein binding of 72% and shows a volume of distribution of 32 L/kg. Studies in rats have shown that tiotropium does not penetrate the blood-brain barrier to any relevant extent.
Olodaterol has a plasma protein binding of approximately 60% and shows a volume of distribution of 1110 L.
Biotransformation: Tiotropium: The extent of metabolism is small. This is evident from 74% of an intravenous dose being excreted in the urine as unchanged drug. The ester tiotropium is nonenzymatically cleaved into its alcohol and acid component (N-methylscopine and dithienylglycolic acid, respectively), both not binding to muscarinic receptors. In vitro experiments with human liver microsomes and human hepatocytes suggest that some further drug (<20% of the dose after intravenous administration) is metabolized by cytochrome P450 (CYP) 2D6 and 3A4 dependent oxidation and subsequent glutathione conjugation to a variety of Phase II-metabolites.
Olodaterol is substantially metabolized by direct glucuronidation and by O-demethylation at the methoxy moiety followed by conjugation. Of the six metabolites identified, only the unconjugated demethylation product (SOM 1522) binds to β2-receptors; this metabolite however is not detectable in plasma after chronic inhalation of the recommended therapeutic dose or doses of up to 4-fold higher. Cytochrome P450 isozymes CYP2C9 and CYP2C8, with negligible contribution of CYP3A4, are involved in the O-demethylation of olodaterol, while uridine diphosphate glycosyl transferase isoforms UGT2B7, UGT1A1, 1A7 and 1A9 were shown to be involved in the formation of olodaterol glucuronides.
Elimination: Tiotropium: Intravenously administered tiotropium is mainly excreted unchanged in urine (74%). The total clearance in healthy volunteers is 880 mL/min. After inhalation by COPD patients to steady-state, urinary excretion is 18.6% of the dose, the remainder being mainly non-absorbed drug in gut that is eliminated via the faeces. The renal clearance of tiotropium exceeds the glomerular filtration rate, indicating active secretion into the urine. The effective half-life of tiotropium following inhalation by COPD patients ranges between 27 and 45 h.
Olodaterol: Total clearance of olodaterol in healthy volunteers is 872 mL/min, and renal clearance is 173 mL/min. The terminal half-life following intravenous administration is 22 hrs. The terminal half-life following inhalation in contrast is about 45 hrs, indicating that the latter is determined by absorption rather than by elimination processes.
Following intravenous administration of [14C]-labelled olodaterol, 38% of the radioactive dose was recovered in the urine and 53% was recovered in feces. The amount of unchanged olodaterol recovered in the urine after intravenous administration was 19%. Following oral administration, only 9% of the radioactivity was recovered in urine, while the major portion was recovered in feces (84%). More than 90% of the dose was excreted within 6 and 5 days following intravenous and oral administration, respectively. Following inhalation, excretion of unchanged olodaterol in urine within the dosing interval in healthy volunteers at steady state accounted for 5-7% of the dose.
Characteristics in Patients: Tiotropium: As expected for all predominantly renally excreted drugs, advancing age was associated with a decrease of tiotropium renal clearance from 347 mL/min in COPD patients <65 years to 275 mL/min in COPD patients ≥65 years. This did not result in a corresponding increase in AUC0-6,ss or Cmax,ss values.
Olodaterol: A pharmacokinetic meta-analysis utilizing data from 2 controlled clinical trials that included 405 patients with COPD and 296 patients with asthma showed that no dose adjustment is necessary due to effects of age, gender and weight on systemic exposure to olodaterol.
Comparison of pharmacokinetic data within and across studies with olodaterol revealed a trend for higher systemic exposure in Japanese and other Asians than in Caucasians.
No safety concerns were identified in clinical studies with olodaterol in Caucasians and Asians of up to one year with olodaterol doses up to twice the recommended therapeutic dose.
Renal Insufficiency: Tiotropium: Following once daily inhaled administration of tiotropium to steady-state in COPD patients with mild renal impairment (CLCR 50-80 mL/min) resulted in slightly higher AUC0-6,ss (between 1.8 to 30% higher) and similar Cmax,ss compared to patients with normal renal function (CLcr >80 mL/min). In subjects with moderate to severe renal impairment (CLCR <50 ml/min) intravenous administration of tiotropium resulted in twofold higher total exposure (82% higher AUC0-4h and 52% higher Cmax) compared to subjects with normal renal function, which was confirmed by observations after dry powder inhalation.
Olodaterol: In subjects with severe renal impairment (CLCR <30 mL/min) systemic exposure to olodaterol was on average 1.4-fold increased. This magnitude of exposure increase does not raise any safety concerns given the safety experience of treatment with olodaterol in clinical studies of up to one year at doses up to twice the recommended therapeutic dose.
Hepatic Insufficiency: Tiotropium: Liver insufficiency is not expected to have any relevant influence on tiotropium pharmacokinetics. Tiotropium is predominantly cleared by renal elimination (74% in young healthy volunteers) and simple non-enzymatic ester cleavage to pharmacologically inactive products.
Olodaterol: In subjects with mild and moderate hepatic impairment systemic exposure to olodaterol was not affected. The effect of severe hepatic impairment on systemic exposure to olodaterol was not investigated.
Drug-Drug Interactions: Olodaterol: Drug-drug interaction studies were carried out using fluconazole as model inhibitor of CYP 2C9 and ketoconazole as potent P-gp and CYP inhibitor.
Fluconazole: Co-administration of 400 mg fluconazole once daily for 14 days had no relevant effect on systemic exposure to olodaterol.
Ketoconazole: Co-administration of 400 mg ketoconazole once daily for 14 days increased olodaterol Cmax by 66% and AUC0-1 by 68%.
Indications/Uses
Spiolto Respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Dosage/Direction for Use
The recommended dose for adults is 5 microgram tiotropium and 5 microgram olodaterol given as two puffs from the Respimat inhaler once daily at the same time of the day (see Instructions for Use under Cautions for Usage).
Elderly: Elderly patients can use SPIOLTO RESPIMAT at the recommended dose.
Hepatic impairment and renal impairment: SPIOLTO RESPIMAT contains tiotropium which is a predominantly renally excreted drug and olodaterol, which is predominantly metabolized in the liver.
Hepatic impairment: Patients with mild and moderate hepatic impairment can use SPIOLTO RESPIMAT at the recommended dose.
There are no data available for use of olodaterol in patients with severe hepatic impairment.
Renal impairment: Renally impaired patients can use SPIOLTO RESPIMAT at the recommended dose.
SPIOLTO RESPIMAT contains tiotropium, which is a predominantly renally excreted drug. Therefore, SPIOLTO RESPIMAT use should be monitored closely in patients with moderate to severe renal impairment.
Paediatric population: There is no relevant use of SPIOLTO RESPIMAT in the paediatric population in COPD. The safety and effectiveness of SPIOLTO RESPIMAT in the paediatric population have not been established.
Overdosage
Symptoms: High doses of tiotropium may lead to anticholinergic signs and symptoms.
No relevant adverse events, beyond dry mouth/throat and dry nasal mucosa in a dose-dependent [10 - 40 μg daily] incidence, were observed following 14-day dosing of up to 40 μg tiotropium inhalation solution in healthy subjects with the exception of pronounced reduction in salivary flow from day 7 onwards. No significant undesirable effects have been observed in six long term studies in COPD patients when a daily dose of 10 μg tiotropium inhalation solution was given over 4 - 48 weeks.
An overdose of olodaterol is likely to lead to exaggerated effects typical of beta2-adrenergic agonists, i.e. myocardial ischemia, hypertension or hypotension, tachycardia, arrhythmias, palpitation, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasms, nausea, fatigue, malaise, hypokalaemia, hyperglycaemia and metabolic acidosis.
Therapy: Treatment with SPIOLTO RESPIMAT should be discontinued. Supportive and symptomatic treatment is indicated. Serious cases should be hospitalized. Use of cardioselective beta-blockers may be considered, but only subject to extreme caution since the use of beta-adrenergic blocker medication may provoke bronchospasm.
Contraindications
SPIOLTO RESPIMAT is contraindicated in patients with hypersensitivity to tiotropium or olodaterol or to any of the excipients.
SPIOLTO RESPIMAT is also contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium.
Special Precautions
General Warnings: SPIOLTO RESPIMAT should not be used more frequently than once daily. SPIOLTO RESPIMAT should not be used in asthma. The efficacy and safety of SPIOLTO RESPIMAT in asthma have not been studied.
Acute bronchospasm: SPIOLTO RESPIMAT is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.
Hypersensitivity: As with all medications, immediate hypersensitivity reactions may occur after administration of SPIOLTO RESPIMAT.
Paradoxical bronchospasm: As with other inhaled medicines SPIOLTO RESPIMAT may result in paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs SPIOLTO RESPIMAT should be discontinued immediately and alternative therapy substituted.
Narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction: Consistent with the anticholinergic activity of tiotropium, SPIOLTO RESPIMAT should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.
Patients with renal impairment: As plasma concentration of tiotropium increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance ≤50 ml/min) Spiolto Respimat should be used only if the expected benefit outweighs the potential risk. There is no long term experience in patients with severe renal impairment (see Pharmacology: Pharmacokinetics under Actions).
Eye symptoms: Patients must be instructed in the correct administration of SPIOLTO RESPIMAT. Care must be taken not to allow the solution or mist to enter into the eyes. Eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop specialist advice should be sought immediately.
Miotic eye drops are not considered to be effective treatment.
Cardiovascular effects: SPIOLTO RESPIMAT contains a long acting beta2-adrenergic agonist. Long acting beta2-adrenergic agonists should be administered with caution in patients with cardiovascular disorders especially coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy and hypertension; in patients with convulsive disorders or thyrotoxicosis, in patients with known or suspected prolongation of the QT interval; and in patients who are unusually responsive to sympathomimetic amines.
Like other beta2-adrenergic agonists, olodaterol may produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms. In case such effects occur, treatment may need to be discontinued. In addition, beta-adrenergic agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave and ST segment depression, although the clinical significance of these observations is unknown.
Hypokalaemia: Beta2-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. In patients with severe COPD, hypokalaemia may be potentiated by hypoxia and concomitant treatment (please refer to Interactions), which may increase the susceptibility to cardiac arrhythmias.
Hyperglycaemia: Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose.
Anaesthesia: Caution needs to be taken in case of a planned operation with halogenated hydrocarbon anaesthetics due to an increased susceptibility to the adverse cardiac effects of beta agonist bronchodilators.
Spiolto Respimat should not be used in conjunction with any other medications containing long-acting beta2-adrenergic agonists.
Patients who have been taking inhaled, short-acting beta2-adrenergic agonists on a regular basis (e.g. four times a day) should be instructed to use them only for symptomatic relief of acute respiratory symptoms.
Effects on ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been performed.
However, patients should be advised that dizziness and blurred vision have been reported with the use of SPIOLTO RESPIMAT. Therefore, caution should be recommended when driving a car or operating machinery. If patients experience such symptoms they should avoid potentially hazardous tasks such as driving or operating machinery.
Use In Pregnancy & Lactation
Pregnancy: There is a limited amount of data from the use of tiotropium in pregnant women. For olodaterol no clinical data on exposed pregnancies are available.
Preclinical studies with tiotropium do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses.
Preclinical data for olodaterol revealed effects typical for beta-adrenergic agonists at high multiples of the therapeutic doses.
As a precautionary measure, it is preferable to avoid the use of SPIOLTO RESPIMAT during pregnancy.
The inhibitory effect of beta-adrenergic agonists, like olodaterol a component of SPIOLTO RESPIMAT on uterine contraction should be taken into account.
Lactation: Clinical data from nursing women exposed to tiotropium and/or olodaterol are not available.
In preclinical studies for both tiotropium and olodaterol the substances and/or its metabolites have been detected in the milk of lactating rats, but it is not known whether tiotropium and/or olodaterol pass into human breast milk.
Therefore, SPIOLTO RESPIMAT should not be used in nursing women unless the expected benefit outweighs any possible risk to the infant.
Fertility: Clinical data on fertility are not available for tiotropium and olodaterol or the combination of both components. Preclinical studies performed with the individual components tiotropium and olodaterol showed no indication of any adverse effect on fertility.
Adverse Reactions
The safety of SPIOLTO RESPIMAT has been evaluated in active-controlled, parallel-group and cross-over clinical trials in overall 7151 patients with COPD. A total of 1988 patients with COPD received the target dose of 5 microgram tiotropium and 5 microgram olodaterol.
Side effects of SPIOLTO RESPIMAT were primarily identified from data obtained in 2 active-controlled, parallel-group, long-term treatment (52 weeks) clinical trials in COPD patients.
In the pooled analysis of these long-term clinical trials the overall incidence of AEs in patients treated with SPIOLTO RESPIMAT was comparable to patients treated with the mono components tiotropium at a dose of 5 microgram or olodaterol at a dose of 5 microgram (74%, 73,3% and 76,6%, respectively). All undesirable effects previously reported with one of the individual components are considered undesirable effects with SPIOLTO RESPIMAT and are included in the adverse reactions listed as follows.
In addition undesirable effects reported with SPIOLTO RESPIMAT, but not with the individual components are included.
Tabulated list of adverse reactions: The adverse reactions are listed by absolute frequency. Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), or very rare (<1/10,000), and not known (cannot be estimated from the available data). (See Table 10.)


Click on icon to see table/diagram/image


Many of the listed undesirable effects can be assigned to either the anticholinergic properties of tiotropium or to the β-adrenergic properties of olodaterol, the components of SPIOLTO RESPIMAT.
In addition the occurrence of other undesirable effects related to the beta-adrenergic agonist class, which are not previously listed, should be taken into consideration, such as arrhythmia, myocardial ischemia, angina pectoris, hypotension, tremor, headache, nervousness, nausea, muscle spasms, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis.
Inform the doctor or pharmacist immediately about side effects that occur while taking the drug.
Drug Interactions
Although no formal drug interaction studies have been performed, tiotropium bromide has been used concomitantly with other drugs commonly used in the treatment of COPD, including, methylxanthines, oral and inhaled steroids, without clinical evidence of drug interactions.
The chronic co-administration of tiotropium bromide with other anticholinergic drugs has not been studied. Therefore, the chronic co-administration of other anticholinergic drugs with SPIOLTO RESPIMAT is not recommended.
Adrenergic agents: Concomitant administration of other adrenergic agents may potentiate the undesirable effects of SPIOLTO RESPIMAT.
Xanthine Derivatives, Steroids or Diuretics: Concomitant treatment with xanthine derivatives, steroids, or non-potassium sparing diuretics may potentiate any hypokalaemic effect of adrenergic agonists (see Precautions).
Beta-blockers: Beta-adrenergic blockers may weaken or antagonize the effect of olodaterol. Cardioselective beta-blockers could be considered, although they should be administered with caution.
MAO Inhibitors, Tricyclic Antidepressants, QTc prolonging drugs: Monoamine oxidase inhibitors, or tricyclic antidepressants or other drugs known to prolong the QTc interval may potentiate the action of SPIOLTO RESPIMAT on the cardiovascular system.
Pharmacokinetic Drug interactions: In a drug interaction study with olodaterol using the strong dual CYP and P-gp inhibitor ketoconazole a 1.7-fold increase of systemic exposure was observed (see Pharmacology: Pharmacokinetics under Actions). No safety concerns were identified in clinical studies of up to one year with olodaterol at doses up to twice the recommended therapeutic dose. No dose adjustment of SPIOLTO RESPIMAT is necessary.
Caution For Usage
Instructions for use: Introduction: SPIOLTO RESPIMAT (tiotropium bromide and olodaterol). Read these Instructions for Use before starting to use SPIOLTO RESPIMAT.
The patient will need to use this inhaler only ONCE A DAY. Each time the patient uses it TAKE TWO PUFFS.
How to care for the SPIOLTO RESPIMAT: Clean the mouthpiece including the metal part inside the mouthpiece with a damp cloth or tissue only, at least once a week.
Any minor discoloration in the mouthpiece does not affect the SPIOLTO RESPIMAT inhaler performance.
When to get a new SPIOLTO RESPIMAT: The SPIOLTO RESPIMAT inhaler contains 60 puffs (30 doses) if used as indicated (two puffs/Once daily).
The dose indicator shows approximately how much medication is left.
When the dose indicator enters the red area of the scale the patient needs to get a new prescription; there is approximately medication for 7 days left (14 puffs).
Once the dose indicator reaches the end of the red scale, the SPIOLTO RESPIMAT locks automatically - no more doses can be released. At this point, the clear base cannot be turned any further.
Three months after first use, the SPIOLTO RESPIMAT should be discarded even if it has not been used.
Prepare for first use: 1. Remove clear base: Keep the cap closed.
Press the safety catch while firmly pulling off the clear base with the other hand.
2. Insert cartridge: Insert the narrow end of the cartridge into the inhaler.
Place the inhaler on a firm surface and push down firmly until it snaps into place.
3. Replace clear base: Put the clear base back into place until it clicks.
4. Turn: Keep the cap closed.
Turn the clear base in the direction of the arrows on the label until it clicks (half a turn).
5. Open: Open the cap until it snaps fully open.
6. Press: Point the inhaler toward the ground.
Press the dose-release button.
Close the cap.
Repeat steps 4-6 until a cloud is visible.
After a cloud is visible, repeat steps 4-6 three more times.
Daily use: TURN: Keep the cap closed.
TURN the clear base in the direction of the arrows on the label until it clicks (half a turn).
OPEN: OPEN the cap until it snaps fully open.
PRESS: Breathe out slowly and fully.
Close the lips around the mouthpiece without covering the air vents.
While taking a slow, deep breath through the mouth, PRESS the dose-release button and continue to breathe in.
Hold the breath for 10 seconds or for as long as comfortable.
Repeat Turn, Open, Press for a total of 2 puffs.
Incompatibilities: Not applicable.
Storage
Store below 30°C. Do not freeze.
Shelf life: 24 months.
In-use shelf-life: 3 months after the cartridge is inserted into the RESPIMAT inhaler.
ATC Classification
R03AL06 - olodaterol and tiotropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Soln for inhalation (clear, colorless) 4 mL (60 puffs) x 1's (+ inhaler).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in